StonvexLoading…
StonvexStonvexStonvexCore line items from CVS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q3 2026 (Est.) Expected 2026-07-29 | Q3 2019 2019-09-30 | Q2 2019 2019-06-30 | Q1 2019 2019-03-31 | Annual 2018 2018-12-31 |
|---|---|---|---|---|---|
Revenue | $101.16B | $189.08B | $124.53B | $61.40B | $193.92B |
Operating Income | Not available | $8.95B | $6.02B | $2.69B | $4.02B |
Net Income | Not available | $4.89B | $3.36B | $1.42B | $-594.00M |
EPS (Diluted) | $1.83 | $3.75 | $2.58 | $1.09 | $-0.57 |
Total Assets | Not available | $220.11B | $218.90B | $219.77B | $196.46B |
Total Liabilities | Not available | $157.18B | $157.31B | $159.76B | $137.91B |
Cash & Equivalents | Not available | $5.19B | $6.06B | $5.90B | $4.06B |
Free Cash Flow OCF − CapEx | Not available | $8.32B | $6.00B | $1.23B | $6.83B |
Shares Outstanding | Not available | 1.30B | 1.30B | 1.30B | 1.29B |